PE Guidelines logo
Pharmacoeconomic Guidelines Around The World

Country/Region: Croatia

Published PE Recommendations
Guide for the Economic Evaluation of Health Technologies: Croatia; as part of the Croatian Guideline for Health Technology Assessment Process and Reporting, 1st ed Zagreb, February 2011
http://aaz.hr/hr/procjena-zdravstvenih-tehnologija/smjernice
PDF in English
http://aaz.hr/sites/default/files/hrvatske_smjernice_za_procjenu_zdravstvenih_tehnologija.pdf

Published PE Recommendations Source:
Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment. The Croatian Guideline for Health Technology Assessment Process and Reporting, 1st ed Zagreb, February 2011.

Additional Information:
Agency for Quality and Accreditation in Health Care and Social Welfare
http://www.aaz.hr

Last Webpage Update: Monday, February 22, 2016

Published PE Recommendations Key Features:

Key Features:  
Title and year of the documentThe Croatian Guideline for Health Technology Assessment Process and Reporting, 1st ed Zagreb, February 2011. Part 6 Guide for the Economic Evaluation of Health Technologies: Croatia 
Affiliation of authorsAgency for Quality and Accreditation in Health Care, Department for Development, Research and Health Technology Assessment and Academia  
Purpose of the documentTo produce credible and standardized information that is relevant and useful to decision makers in Croatian publicly funded health care system, and to meet their needs for reliable, consistent, timely and relevant HTA information.
Croatian HTA reports should serve as recommendations, with aims to support policymakers at national level, particularly Croatian Ministry of Health and Social Welfare and Croatian Institute for Health Insurance, in making evidence-informed decisions on the strategic planning, investment, management and the implementation of technologies in health care, on funding (reimbursement) and coverage of health technologies, and, on hospital level, on requests from hospital directors and policy teams.  
Standard reporting format includedYes  
DisclosureYes  
Target audience of funding/ author's interestsPolicymakers at national level, particularly Croatian Ministry of Health and Social Welfare and Croatian Institute for Health Insurance, and, on hospital level, hospital directors and policy teams. 
PerspectiveCroatian Institute for Health Insurance (as public payer) (societal perspective, including all cost and benefits outside the health care system, may be presented in addition, if considered relevant for some topics) 
IndicationLicensed one(s)  
Target populationYes 
Subgroup analysisYes 
Choice of comparatorTherapies routinely used in the Croatian health system, including technologies regarded as current best practice. 
Time horizonSufficiently long to reflect all important differences in costs or outcomes between the technologies being compared 
Assumptions requiredYes 
Preferred analytical techniqueCost-effectiveness analysis (CEA) or Cost-utility analysis, (CUA), depending on the particularities of the technology being assessed 
Costs to be includedYes 
Source of costsDirect cost relevant to Croatian Institute for Health Insurance (where measurable and relevant, indirect costs and cost falling outside of Croatian Institute for Health Insurance should be reported separately) 
ModelingYes  
Systematic review of evidencesYes  
Preference for effectiveness over efficacyYes, modeling and/or sensitivity analysis should be used to extrapolate efficacy data 
Preferred outcome measureMeasure of health effects: Natural units (CEA) or QALYs (CUA) Measurement of QALY gains: Reported directly by patients and/or informal caregivers 
Preferred method to derive utilityEQ-5D 
Equity issues statedYes 
Discounting costsAn annual rate of 5% on both costs and health effects (in sensitivity analyses between 3% and 10%) 
Discounting outcomesAn annual rate of 5% on both costs and health effects (in sensitivity analyses between 3% and 10%) 
Sensitivity analysis-parameters and rangeOn uncertain parameters 
Sensitivity analysis-methodsProbabilistic sensitivity analysis 
Presenting resultsFor clarity, reproducibility, and future use of data, results of total costs and total gains should be clearly stated 
Incremental analysisYes 
Total costs vs effectiveness (cost/effectiveness ratio)Yes 
Portability of results (Generalizability)Yes 
Financial impact analysisBudget Impact Analysis (BIA) is mandatory for submission to the Croatian Health Insurance Fund, and this should be done according the ISPOR BIA guidelines 
Mandatory or recommended or voluntaryRecommended 

Acknowledgement: Mirjana Huic, MD, PhD, Department for Development, Research and Health Technology Assessment; Agency for Quality and Accreditation in Health Care and Social Welfare contributed to the key feature form

Country Selection Page | PE Guidelines Index Page